- Neuren Pharmaceuticals focuses on developing new drug therapies for serious neurological disorders
- Trofinetide and NNZ-2591 are two new drug candidates for Neuren
- The Neuren share price has gained nearly 197% over the last 52 weeks
Neuren Pharmaceuticals (ASX: NEU) is moving forward in the development of new drug therapies to cure multiple serious neurological disorders, which usually begin in early childhood and have no approved medicines. The company’s commercial partner is Acadia Pharmaceuticals, a US-based healthcare company.
A glance at Neuren’s technology pipeline